S E Christensen
Overview
Explore the profile of S E Christensen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
736
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Christensen S, Weeke J, Orskov H, Kaal A, Lund E, Jorgensen J, et al.
Metabolism
. 1992 Sep;
41(9 Suppl 2):44-50.
PMID: 1518433
Twenty-five acromegalic patients were studied during 6 years of treatment with octreotide, with a particular focus on the following parameters: (1) Administration schedule: in 10 patients, continuous subcutaneous (SC) octreotide...
12.
Weeke J, Christensen S, Orskov H, Kaal A, Pedersen M, Illum P, et al.
J Clin Endocrinol Metab
. 1992 Jul;
75(1):163-9.
PMID: 1619006
Fifteen acromegalic patients received four single doses of octreotide in random order (500 micrograms, 1000 micrograms, and 2000 micrograms applied intranasally and 100 micrograms given sc). Serum octreotide and GH...
13.
Moiniche S, Hansen B, Christensen S, Dahl J, Kehlet H
Ugeskr Laeger
. 1992 May;
154(21):1495-9.
PMID: 1598721
Thirteen consecutive patients were submitted to hip-replacement by Müller's method under epidural analgesia and were treated for postoperative pain with balanced analgesia by means of continuous epidural infusion of a...
14.
Moller N, Schmitz O, Joorgensen J, Astrup J, Bak J, Christensen S, et al.
J Clin Endocrinol Metab
. 1992 May;
74(5):1012-9.
PMID: 1569148
Active acromegaly is characterized by inappropriate tissue growth, increased mortality, and perturbations of intermediary metabolism. It is, in general, not well described to which extent these disturbances are normalized after...
15.
Christensen S, Weeke J, Kaal A, Harris A, Orskov H
Horm Metab Res
. 1992 May;
24(5):237-9.
PMID: 1398464
The acute (TRH-stimulation test), intermediate (0-6 days administration), and long-term (0-30 months administration) effects of SMS 201-995 (octreotide) treatment on thyroid function were studied. Subcutaneous injection of 100 micrograms SMS...
16.
Nielsen H, Brixen K, Kassem M, Christensen S, Mosekilde L
Calcif Tissue Int
. 1991 Dec;
49(6):373-7.
PMID: 1818760
We examined the role of sleep, growth hormone (GH), and parathyroid hormone [PTH(1-84)] as regulators of the diurnal rhythm of the osteoblastic bone marker, serum osteocalcin (OC). Nine normal subjects...
17.
Orskov H, Christensen S, Weeke J, Kaal A, Harris A
Clin Endocrinol (Oxf)
. 1991 May;
34(5):395-8.
PMID: 2060149
Two patients developed specific IgG antibodies against octreotide after 2-3 years' treatment for acromegaly with this long acting somatostatin analogue. The presence of these antibodies reduced the plasma disappearance rate...
18.
Wu J, Christensen S
J Clin Lab Anal
. 1991 Jan;
5(3):228-32.
PMID: 2061748
Determining serum CA 19-9 using regular Centocor kit frequently requires numerous repeats when specimens contain highly elevated levels of CA 19-9. We found that the number of repeats could be...
19.
Lund E, Jorgensen J, Christensen S, Weeke J, Orskov H, Harris A
Neuroradiology
. 1991 Jan;
33(2):162-4.
PMID: 2046904
Ten patients with acromegaly were treated with the long-acting somatostatin analogue, Sandostatin (SMS 201-995, octreotide) for more than one year. Computerized tomography was performed before and on 4 different occasions...
20.
Pedersen M, Christensen S, Christiansen J, Pedersen E, Mogensen C, Orskov H
Diabet Med
. 1990 May;
7(4):304-9.
PMID: 2140082
Suppression of growth hormone by means of somatostatin has been suggested as a possible adjunct therapy in Type 1 diabetes. To assess the acute effect of the somatostatin analogue SMS...